AR050930A1 - Metodos para tratar enfermedades proliferativas de la piel mediante el uso de derivados de carbazol - Google Patents
Metodos para tratar enfermedades proliferativas de la piel mediante el uso de derivados de carbazolInfo
- Publication number
- AR050930A1 AR050930A1 ARP050103785A ARP050103785A AR050930A1 AR 050930 A1 AR050930 A1 AR 050930A1 AR P050103785 A ARP050103785 A AR P050103785A AR P050103785 A ARP050103785 A AR P050103785A AR 050930 A1 AR050930 A1 AR 050930A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- independently
- heteroaryl
- pnr7r8
- Prior art date
Links
- 230000002062 proliferating effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical class C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 13
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000002252 acyl group Chemical group 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 150000002772 monosaccharides Chemical class 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- 206010027145 Melanocytic naevus Diseases 0.000 abstract 2
- 208000007256 Nevus Diseases 0.000 abstract 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 abstract 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 abstract 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 abstract 1
- 208000029966 Hutchinson Melanotic Freckle Diseases 0.000 abstract 1
- 208000007766 Kaposi sarcoma Diseases 0.000 abstract 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010048214 Xanthoma Diseases 0.000 abstract 1
- 206010048215 Xanthomatosis Diseases 0.000 abstract 1
- 208000009621 actinic keratosis Diseases 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 208000024386 fungal infectious disease Diseases 0.000 abstract 1
- 229940084434 fungoid Drugs 0.000 abstract 1
- 108010015792 glycyllysine Proteins 0.000 abstract 1
- 201000011066 hemangioma Diseases 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 206010024217 lentigo Diseases 0.000 abstract 1
- 208000008585 mastocytosis Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000011645 metastatic carcinoma Diseases 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- QNMMYUBZGLXCCK-UHFFFAOYSA-N pyrrolo[3,2-a]carbazole Chemical compound N1=C2C=CC=CC2=C2C1=C1C=CN=C1C=C2 QNMMYUBZGLXCCK-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60920304P | 2004-09-10 | 2004-09-10 | |
| US11/222,409 US20060058250A1 (en) | 2004-09-10 | 2005-09-08 | Methods of treating proliferative skin diseases using carbazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050930A1 true AR050930A1 (es) | 2006-12-06 |
Family
ID=36034857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103785A AR050930A1 (es) | 2004-09-10 | 2005-09-09 | Metodos para tratar enfermedades proliferativas de la piel mediante el uso de derivados de carbazol |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060058250A1 (https=) |
| EP (1) | EP1786418A1 (https=) |
| JP (1) | JP2008512497A (https=) |
| KR (1) | KR20070113186A (https=) |
| AR (1) | AR050930A1 (https=) |
| AU (1) | AU2005285007A1 (https=) |
| BR (1) | BRPI0515115A (https=) |
| CA (1) | CA2577024A1 (https=) |
| IL (1) | IL181003A0 (https=) |
| MX (1) | MX2007002532A (https=) |
| MY (1) | MY156431A (https=) |
| NO (1) | NO20071052L (https=) |
| TW (1) | TW200621266A (https=) |
| WO (1) | WO2006031772A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114110A1 (es) | 2018-02-28 | 2020-07-22 | Lilly Co Eli | Anticuerpo anti-trka |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| DK1044203T3 (da) * | 1997-12-31 | 2003-07-14 | Cephalon Inc | 3'-epimere K-252a-derivater |
| US6127401A (en) * | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
| US6013646A (en) * | 1998-07-02 | 2000-01-11 | Bayer Corporation | Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
| US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
| EP1309721A2 (en) * | 2000-08-11 | 2003-05-14 | Cephalon, Inc. | Modulating multiple lineage kinase proteins |
| US6667173B2 (en) * | 2000-12-01 | 2003-12-23 | The Schepens Eye Research Institute | Nucleic acids encoding platelet derived growth factor-alpha receptors |
| US7241779B2 (en) * | 2003-12-23 | 2007-07-10 | Cephalon, Inc. | Fused pyrrolocarbazoles |
-
2005
- 2005-09-08 US US11/222,409 patent/US20060058250A1/en not_active Abandoned
- 2005-09-09 JP JP2007531441A patent/JP2008512497A/ja not_active Withdrawn
- 2005-09-09 AR ARP050103785A patent/AR050930A1/es unknown
- 2005-09-09 CA CA002577024A patent/CA2577024A1/en not_active Abandoned
- 2005-09-09 KR KR1020077008005A patent/KR20070113186A/ko not_active Withdrawn
- 2005-09-09 EP EP05796536A patent/EP1786418A1/en not_active Ceased
- 2005-09-09 AU AU2005285007A patent/AU2005285007A1/en not_active Abandoned
- 2005-09-09 MY MYPI20054257A patent/MY156431A/en unknown
- 2005-09-09 BR BRPI0515115-5A patent/BRPI0515115A/pt not_active IP Right Cessation
- 2005-09-09 WO PCT/US2005/032489 patent/WO2006031772A1/en not_active Ceased
- 2005-09-09 TW TW094131097A patent/TW200621266A/zh unknown
- 2005-09-09 MX MX2007002532A patent/MX2007002532A/es not_active Application Discontinuation
-
2007
- 2007-01-28 IL IL181003A patent/IL181003A0/en unknown
- 2007-02-23 NO NO20071052A patent/NO20071052L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008512497A (ja) | 2008-04-24 |
| BRPI0515115A (pt) | 2008-07-01 |
| MX2007002532A (es) | 2007-05-09 |
| EP1786418A1 (en) | 2007-05-23 |
| IL181003A0 (en) | 2007-07-04 |
| TW200621266A (en) | 2006-07-01 |
| AU2005285007A1 (en) | 2006-03-23 |
| KR20070113186A (ko) | 2007-11-28 |
| WO2006031772A1 (en) | 2006-03-23 |
| US20060058250A1 (en) | 2006-03-16 |
| NO20071052L (no) | 2007-04-03 |
| MY156431A (en) | 2016-02-26 |
| CA2577024A1 (en) | 2006-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062503A1 (es) | Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor. | |
| AR117544A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| UY28756A1 (es) | Compuestos | |
| AR087184A1 (es) | Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| UY28755A1 (es) | Compuestos | |
| AR069801A1 (es) | Derivados de aminotriazol | |
| UY33961A (es) | Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona | |
| AR049536A1 (es) | Compuestos heterociclicos condensados con actividad inhibitoria de la proteina tirosina cinasa; una composicion farmaceutica que los contiene como principio activo y su utilizacion en el tratamiento del cancer. | |
| ECSP109903A (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
| AR082574A1 (es) | Compuestos de 1,4,5,6-tetrahidro-pirimidin-2-ilamina, composiciones farmaceuticas en base al compuesto y procedimiento para la obtencion del compuesto | |
| BR112013007696A2 (pt) | composto, composição farmacêutica, usos do referido composto e da referida composição | |
| AR084290A1 (es) | Inhibidores de neprilisina, metodos para su preparacion e intermediarios utilizados en los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por la inhibicion de nep | |
| AR041719A1 (es) | Derivados de metilenurea como inhibidores de la raf-quinasa | |
| PE20121091A1 (es) | Derivados de purina o deazapurina utiles en el tratamiento de (inter alia) infecciones virales | |
| EA201000642A1 (ru) | 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы | |
| AR056850A1 (es) | MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| CY1120478T1 (el) | Παραγωγα 2,6-υποκατεστημενης πουρινης και η χρηση αυτων στην αγωγη υπερπλαστικων διαταραχων | |
| AR045033A1 (es) | Derivados de malonamida, metodo de obtencion y composiciones farmaceuticas que los contienen. | |
| CY1116439T1 (el) | Τριαζολοπυριδινες | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| CR11208A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas | |
| CL2011001413A1 (es) | Compuestos derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para la prevencion o el tratamiento de una infeccion bacteriana. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |